These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 9643348

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia.
    Horie Y, Fazio S, Westerlund JR, Weisgraber KH, Rall SC.
    J Biol Chem; 1992 Jan 25; 267(3):1962-8. PubMed ID: 1730728
    [Abstract] [Full Text] [Related]

  • 4. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia.
    März W, Hoffmann MM, Scharnagl H, Fisher E, Chen M, Nauck M, Feussner G, Wieland H.
    J Lipid Res; 1998 Mar 25; 39(3):658-69. PubMed ID: 9548597
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.
    Wardell MR, Rall SC, Brennan SO, Nye ER, George PM, Janus ED, Weisgraber KH.
    J Lipid Res; 1990 Mar 25; 31(3):535-43. PubMed ID: 2341812
    [Abstract] [Full Text] [Related]

  • 8. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia.
    Ji ZS, Fazio S, Mahley RW.
    J Biol Chem; 1994 May 06; 269(18):13421-8. PubMed ID: 8175773
    [Abstract] [Full Text] [Related]

  • 9. Chylomicron remnant uptake in the livers of mice expressing human apolipoproteins E3, E2 (Arg158-->Cys), and E3-Leiden.
    Lee SJ, Grosskopf I, Choi SY, Cooper AD.
    J Lipid Res; 2004 Dec 06; 45(12):2199-210. PubMed ID: 15466367
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of macrophage-derived mouse ApoE, human ApoE3-Leiden, and human ApoE2 (Arg158-->Cys) on cholesterol levels and atherosclerosis in ApoE-deficient mice.
    Van Eck M, Herijgers N, Van Dijk KW, Havekes LM, Hofker MH, Groot PH, Van Berkel TJ.
    Arterioscler Thromb Vasc Biol; 2000 Jan 06; 20(1):119-27. PubMed ID: 10634808
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation.
    Innerarity TL, Weisgraber KH, Arnold KS, Rall SC, Mahley RW.
    J Biol Chem; 1984 Jun 10; 259(11):7261-7. PubMed ID: 6327714
    [Abstract] [Full Text] [Related]

  • 15. Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans.
    Ji ZS, Fazio S, Lee YL, Mahley RW.
    J Biol Chem; 1994 Jan 28; 269(4):2764-72. PubMed ID: 8300609
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Preferential association of apolipoprotein E Leiden with very low density lipoproteins of human plasma.
    Fazio S, Horie Y, Weisgraber KH, Havekes LM, Rall SC.
    J Lipid Res; 1993 Mar 28; 34(3):447-53. PubMed ID: 8468528
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Human apolipoprotein E. Receptor binding activity of truncated variants with carboxyl-terminal deletions.
    Lalazar A, Mahley RW.
    J Biol Chem; 1989 May 25; 264(15):8447-50. PubMed ID: 2542277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.